

Cite this: *Chem. Sci.*, 2025, 16, 19632

All publication charges for this article have been paid for by the Royal Society of Chemistry

Rationally designed sonocatalyst-enhanced supramolecular ferroptosis inducers for effective cancer therapy

Yida Pang,^{†ad} Yong Luo,^{†ac} Ting Liu,^{†e} Qian Li,^{†a} Longcan Mei,^a Junhua Zhang,^a Chonglu Li,^{id}*^b Junrong Li^{*a} and Yao Sun^{id}*^{ad}

Ferroptosis is a promising strategy against apoptosis-resistant tumors, yet traditional iron-induced approaches face safety issues and unsatisfied efficacy within complex tumor microenvironments, highlighting the need for biocompatible and highly effective ferroptosis inducers. Herein, we rationally constructed a series of supramolecular ferroptosis inducers (**Ru1–Ru3**) with sonosensitivity and sonocatalytic properties *via* molecular engineering, designed for cancer treatment through near-infrared fluorescence-guided sonodynamic therapy. Among them, **Ru3** exhibited high ultrasound-triggered ¹O₂ generation efficiency ($\Phi_{\Delta} = 0.89$) owing to its extended π -conjugated system and enhanced intramolecular charge transfer effect. Moreover, **Ru3** possesses catalase mimic and peroxidase mimic activities, significantly improving ROS generation and diversifying ROS species. Further studies revealed that **Ru3** localized predominantly in lysosomes, where it induced lysosomal membrane permeabilization and activated ferritinophagy under US irradiation, leading to the release of iron ions into the cytosol and triggering a Fenton reaction. Furthermore, **Ru3** catalyzed the depletion of GSH and the oxidation of NADPH, disrupting redox homeostasis. These effects collectively suppressed GPX4 activity, promoted lipid LPO accumulation, and ultimately enhanced ferroptosis. *In vivo* experiments confirmed that US-activated **Ru3** effectively inhibited 4T1 tumor growth with favorable biosafety. This work provides a research framework for the design of next generation ferroptosis inducers.

Received 30th July 2025
Accepted 10th September 2025

DOI: 10.1039/d5sc05712d

rsc.li/chemical-science

Introduction

Despite significant advances in cancer treatment, malignancies with high incidence and mortality rates continue to pose a major threat to human health.^{1–3} Sonodynamic therapy (SDT) has emerged as a promising anticancer approach, leveraging sonosensitizers to generate cytotoxic singlet oxygen (¹O₂) upon ultrasound (US) irradiation, effectively eliminating cancer cells. SDT offers several advantages, including precise spatiotemporal control, non-invasive application, and deep tissue penetration (>10 cm).⁴ The primary mechanism underlying its anticancer

effects involves caspase-dependent apoptosis.^{5,6} However, the overexpression of anti-apoptotic proteins in malignant cells fosters resistance to apoptosis-inducing agents, thus diminishing the therapeutic efficacy of SDT.^{7–9} This underscores the urgent need to explore novel, non-apoptotic mechanisms of cell death to further enhance the effectiveness of SDT.

Ferrous accumulation- and lipid peroxidation (LPO)-mediated ferroptosis, a non-apoptotic cell death pathway, has garnered increasing attention.^{10–12} However, the direct delivery of iron may induce severe side effects, such as hypersensitivity reactions in normal tissues. Therefore, employing non-iron-dependent agents to induce LPO could be safer for triggering ferroptosis in tumor cells. As the primary ‘executor’ in SDT, reactive oxygen species (ROS) can oxidize polyunsaturated fatty acids to lipid peroxides, ultimately leading to ferroptosis.^{13–17} The key factor promoting ferroptosis is the elevation of intracellular ROS levels. Recent studies have shown that organic sonosensitizers, with well-defined structures and flexible designs, can effectively generate ROS under US irradiation.^{18–22} However, most traditional sensitizers (e.g., cyanine and porphyrin) exhibit low ROS generation efficiency and are prone to ROS quenching.^{23–26} On the other hand, the hypoxic tumor microenvironment (TME) and the overexpression of reductive substances, such as nicotinamide adenine dinucleotide

^aKey Laboratory of Pesticides and Chemical Biology, Ministry of Education, International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University, Wuhan 430079, China. E-mail: sunyao@ccnu.edu.cn

^bHubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Public Health, Medical College, Wuhan University of Science and Technology, Wuhan, 430065, China. E-mail: lichonglu@wust.edu.cn

^cSchool of Materials Science and Engineering, Wuhan University of Technology, Wuhan 430079, China

^dHubei Jiangxia Laboratory, Wuhan 430200, China

^eWuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, China

[†] These authors contributed equally to this work.

phosphate (NADPH) and glutathione (GSH), can directly or indirectly reduce ROS levels.²⁷ NADPH plays a key role in the recycling of GSH by donating electrons to glutathione reductase, which reduces oxidized glutathione (GSSG) back to GSH. GSH plays a critical role in supporting the antioxidant function of glutathione peroxidase 4 (GPX4), which converts harmful lipid peroxides into benign lipid alcohols, thereby protecting cells. Specifically, by directly affecting NADPH and depleting GSH, the activity of GPX4 can be inhibited, disrupting the redox balance in tumor cells and promoting ROS-mediated ferroptosis.²⁸ Therefore, in the development of efficient sonosensitizers, it is crucial to consider their inherent multifunctionality, including the ability to alleviate hypoxia and disrupt antioxidant defense systems, to more effectively induce ferroptosis.

Recent studies have shown that supramolecular coordination complexes (SCCs), including Pt(II)- or Ru(II)-based SCCs, *etc.*, demonstrate distinct advantages over small molecular precursors in applications such as bioimaging, photodynamic therapy, and SDT.^{29–33} The formation of SCCs effectively confines sonosensitizers within a rigid structure, thereby minimizing the aggregation-induced ROS quenching effects. Furthermore, the incorporation of heavy metals such as the Ru atom into SCCs enhances intersystem crossing (ISC) and intramolecular charge transfer (ICT) processes, promoting the generation of sonosensitizer-induced ROS.^{34–36} More importantly, the presence of Ru(II) metal centers in SCCs, with their rich redox, optoelectronic, and sonocatalytic properties, may endow these complexes with significant potential for mimicking enzymatic and sonocatalytic activities, particularly in adapting to the complex tumor microenvironment.^{37–40} However, the use of SCCs as potential US-activated ferroptosis inducers remains an underexplored area.

In this study, we successfully designed and synthesized a series of supramolecular ferroptosis inducers (**Ru1–Ru3**) *via* molecular engineering, which possess sonosensitizing and sonocatalytic properties for near-infrared (NIR) fluorescence-guided SDT. Among them, **Ru3** exhibited superior ¹O₂ generation capability ($\Phi_{\Delta} = 0.89$), attributed to its larger π -conjugated system and enhanced ICT effect, compared to homologues **Ru1** ($\Phi_{\Delta} = 0.64$) and **Ru2** ($\Phi_{\Delta} = 0.82$). *In vitro* studies demonstrated that **Ru3** triggered a cascade of molecular events under US activation: first, **Ru3** displayed catalase (CAT)-mimic and peroxidase (POD)-mimic catalytic activities, significantly enhancing ROS generation and expanding their diversity. And **Ru3** mainly accumulated in lysosomes, where the ROS generated increased lysosomes' membrane permeability (LMP), activated ferritinophagy, and released Fe²⁺ into the cytoplasm, where it catalyzed the Fenton reaction, further amplifying oxidative stress. More importantly, **Ru3** significantly disrupted cellular redox homeostasis by catalyzing GSH depletion and promoting NADPH oxidation. These effects collectively suppressed GPX4 activity, promoted lipid LPO accumulation, and ultimately enhanced ferroptosis. Finally, *in vivo* experiments demonstrated that US-activated **Ru3** can effectively and safely ablate tumors in 4T1 tumor-bearing mice under NIR fluorescence-guided assistance. Therefore, this study provides a promising strategy for the development of long-wavelength-

emitting supramolecular ferroptosis inducers with potential clinical applications.


Results and discussion

Design, synthesis, and characterization of Ru(II) metallacycles

To develop supramolecular ferroptosis inducers with high ROS generation efficiency and sonocatalytic capability, a series of novel sonosensitizers were synthesized through rational molecular design and structural modifications. In this design, thienothiadiazole (TTD) was selected as an electron-deficient core to construct a donor–acceptor–donor (D–A–D) conjugated structure, considering that the strong push–pull electron effect would favor enhanced ROS generation.^{41,42} First, **L-1** was developed by using sterically hindered 3-hexylthienyl-substituted pyridine as the electron donor. Based on thienyl donor engineering, **L-2** was obtained by introducing a phenyl ring structure to further expand the π -conjugation. To further enhance the ICT effect, **L-3** was synthesized by incorporating a piperazine structure with stronger electron-donating ability. The chemical structures of **L-1** to **L-3** were comprehensively characterized using ¹H NMR, ¹³C NMR, and MALDI-TOF MS (Fig. S1–S24). Furthermore, density functional theory (DFT) calculations were performed using Gaussian 09 to determine the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) of **L-1**, **L-2**, and **L-3** (Fig. S25). The results showed that the energy gaps of **L-1** (1.74 eV), **L-2** (1.66 eV), and **L-3** (1.59 eV) gradually decreased, validating their potential as sonosensitizers.^{43,44} To further enhance the ROS generation efficiency and impart catalytic properties to these sonosensitizers, we chose a half-sandwich Ru(II) acceptor, with low dark toxicity and high ROS yield,^{45,46} to self-assemble with **L-1**, **L-2**, and **L-3** at a 1 : 1 molar ratio to form SCCs, named **Ru1**, **Ru2**, and **Ru3** (Scheme 1). Compared to the individual small-molecule precursors, the rigid structure and incorporation of heavy metal Ru in SCCs may enhance ROS yield under US activation. More critically, the presence of Ru(II) metal centers in SCCs, with their rich redox, optoelectronic, and catalytic capabilities, may endow these SCCs with significant potential for mimicking enzymatic and sonocatalytic activities, particularly in adapting to the complex tumor microenvironment.

The SCCs, **Ru1**, **Ru2**, and **Ru3**, were synthesized through the reaction of **L-1**, **L-2**, and **L-3** with a Ru(II) acceptor in a 1 : 1 methanol/chloroform mixture, stirred at room temperature for 12 hours, affording total yields of 6.48% (**Ru1**), 4.10% (**Ru2**), and 2.43% (**Ru3**), respectively, as detailed in the SI. To characterize the synthesized SCCs, we initially employed ¹H NMR and 2D COSY (Fig. S26–S37). As shown in Fig. 1a and b, a downfield shift of the pyridine proton peak (*H_a*) was observed compared to the corresponding ligands, with chemical shifts of 8.69–8.83 ppm for **Ru1**, 8.74–8.87 ppm for **Ru2**, and 8.35–8.71 ppm for **Ru3**. For **Ru1**, **Ru2**, and **Ru3**, the proton *H₁* of the SCCs was upfield-shifted by approximately 0.20, 0.40, and 0.24 ppm, respectively, relative to the proton *H₁* of the free Ru(II) receptor, while proton *H₂* was upfield-shifted by approximately 0.16, 0.17, and 0.21 ppm, respectively. These observed chemical shift changes during the self-assembly process are primarily





Scheme 1 Schematic illustration of the supramolecular ferroptosis inducer **Ru3** modulating the tumor microenvironment under US irradiation for tumor therapy. (a) Molecular engineering strategy used for the synthesis of **Ru3**. (b) The potential anti-tumor mechanisms of **Ru3**.

attributed to the decrease in electron density when the TTD-based precursors coordinate to the electron-deficient Ru(II) centers. The 2D COSY spectra further confirmed the correct assignment of each proton in **Ru1**, **Ru2**, and **Ru3**. The clear spectra and distinctive NMR signals from both ^1H NMR and 2D COSY spectra support the formation of these discrete SCCs. To further confirm the assembly of the SCCs, electrospray ionization time-of-flight mass spectrometry (ESI-TOF-MS) was carried out (Fig. 1c). Characteristic peaks corresponding to the elimination of trifluoromethanesulfonate (OTf^-) counterions were observed, indicating successful formation of the $[2 + 2]$ rectangular SCCs, with m/z values of 975.21 for $[\text{Ru1-3OTf}]^{3+}$, 1076.35 for $[\text{Ru2-3OTf}]^{3+}$, and 1189.69 for $[\text{Ru3-3OTf}]^{3+}$. And all assigned isotope peaks closely matched the theoretical distribution, confirming that **Ru1**, **Ru2**, and **Ru3** have the anticipated $[2 + 2]$ assembly structure (Fig. S29, S33 and S37). Finally, DFT calculations were performed to optimize the most stable conformations of **Ru1**, **Ru2**, and **Ru3**. These calculations revealed that all three SCCs adopt a planar rectangular geometry (Fig. 1d and S38), with approximate cavity dimensions of 7.84/21.64 Å, 7.78/29.36 Å, and 7.75/37.31 Å (width/length) for **Ru1**, **Ru2**, and **Ru3**, respectively. These combined results confirm the successful self-assembly of the designed SCCs, **Ru1**, **Ru2**, and **Ru3**.

Photophysical properties, sonodynamic performance, and sonocatalytic activity studies

Based on these molecules, we subsequently investigated the photophysical and sonodynamic properties of **Ru1**, **Ru2**, and **Ru3**. Ultraviolet-visible (UV-vis) absorption and photoluminescence (PL) spectroscopy were employed to study the optical properties of these molecules in dimethyl sulfoxide (DMSO). **Ru1**, **Ru2**, and **Ru3** exhibited maximum absorption wavelengths at 632 nm, 664 and 712 nm, respectively, which were similar to the absorption bands of precursors **L-1** to **L-3** (Fig. 2a and S39). Additionally, the maximum emission wavelengths of these molecules were observed at 944 nm, 959 nm and 1032 nm (with 808 nm as the excitation wavelength), indicating their potential application in NIR fluorescence imaging. Notably, compared to **Ru1** and **Ru2**, **Ru3** exhibited a significant redshift in both absorption and emission wavelengths, ascribed to the expanded π -conjugated system and enhanced ICT in the molecular backbone.

Next, the chemical stability and sonostability of **Ru1**, **Ru2**, and **Ru3** were evaluated by monitoring changes in their absorption spectra. As shown in Fig. 2b, S40 and S41, after incubating in phosphate-buffered saline (PBS) or 10% fetal






Fig. 1 The characterization of SCCs Ru1–Ru3. (a) The chemical structure of Ru1, Ru2 and Ru3. (b) The partial ¹H NMR (400 MHz, 298 K) spectra of metallacycles Ru1–Ru3. (top: acceptor, middle: SCCs, and bottom: ligand) (c) Calculated and experimental ESI-TOF-MS spectra of Ru1 ([Ru1-3OTf]³⁺), Ru2 ([Ru2-3OTf]³⁺), and Ru3 ([Ru3-3OTf]³⁺). (d) Optimized molecular model of Ru3, top view (left), side view (right). For clarity, counterions and hydrogen atoms are omitted.

bovine serum (FBS) for 6 days, no significant degradation in their absorption spectra was observed, indicating strong stability under physiological conditions. To assess the sonodynamic performance of these sonosensitizers, the ROS generation efficiency of Ru1, Ru2, and Ru3 was evaluated using 2',7'-dichlorofluorescein (DCFH) as an indicator. Previous literature reports indicate that SDT commonly employs low-intensity focused US in a frequency range of 0.5–2 MHz. Among these, 1 MHz offers a suitable balance between spatial resolution, controllability and ROS production efficiency, providing sufficient tissue penetration depth while minimizing tissue damage.^{4,7–9} Upon US irradiation (1 W cm^{−2}, 1 MHz), DCFH

alone did not produce fluorescence. Interestingly, after 5 minutes of irradiation, the DCF fluorescence intensity increased by 7.21-fold, 10.14-fold, and 14.31-fold for Ru1, Ru2, and Ru3, respectively (Fig. 2c). These results demonstrated that Ru3 has significantly higher ROS generation efficiency than Ru1 and Ru2. Furthermore, electron paramagnetic resonance (EPR) spectroscopy was conducted to assess the types of ROS generated by Ru1, Ru2, and Ru3 under US irradiation. Among them, ¹O₂ was detected using 2,2,6,6-tetramethylpiperidine (TEMP) as the indicator, while hydroxyl radicals ([•]OH) and superoxide anions (O₂^{•−}) were detected using 5,5-dimethyl-1-pyrroline *N*-oxide (DMPO). As shown in Fig. S42, under US irradiation, Ru1,




Fig. 2 *In vitro* photophysical properties, sonodynamic performance, and sonocatalytic activity of SCCs **Ru3**. (a) Normalized absorption spectra and the emission spectra ($\lambda_{\text{ex}} = 808 \text{ nm}$) of **Ru1**–**Ru3** in DMSO. (b) Normalized absorption spectra of **Ru1**–**Ru3** after incubation in PBS for 1–6 d. (c) Normalized absorption spectra of **Ru1**–**Ru3** in DMF under US irradiation (1 W cm^{-2}). (d) Fluorescent images of DCFH for detecting ROS generation by **Ru1**–**Ru3** in different ratios of DMF and H_2O during US irradiation. (e) Average fluorescence intensity of RDPP induced by **Ru3** and Rubpy. (f) The DO (ΔO_2) production after H_2O_2 co-incubation with **Ru3**. (g) UV/vis absorption spectra of MB after co-incubation with/or H_2O_2 and **Ru3**. (h) Time-dependent GSH consumption perform after co-incubation with **Ru3** or H_2O_2 using DTNB as an indicator ($n = 3$, mean $\pm$ SD). (i) Average absorption spectra of NADPH after co-incubation with **Ru3** at different time points in PBS solution. (j) Schematic illustration of the sonocatalytic capability of **Ru3**.

Ru2, and **Ru3** primarily generated $^1\text{O}_2$, with **Ru3** exhibiting the highest efficiency. The $^1\text{O}_2$ quantum yields (Φ_Δ) of **Ru1**, **Ru2**, and **Ru3** under US irradiation were determined to be 0.64, 0.82, and 0.89, respectively, using methylene blue (MB, $\Phi_\Delta = 0.52$) as a reference sonosensitizer (Fig. S43). These three sonosensitizers produced negligible amounts of $\cdot\text{OH}$ and $\text{O}_2^{\cdot-}$ (Fig. S44 and S45).

Previous studies have demonstrated that the incorporation of heavy atoms such as Ru in SCCs enhances ISC, thereby promoting ROS generation under external energy stimuli.⁴⁷ To explore the underlying mechanisms, we performed geometry optimization and molecular orbital analysis of **Ru1** to **Ru3** using Gaussian 09. The results indicate that, compared to **Ru1** and

Ru2, **Ru3** has the smallest singlet-triplet energy gap (Δ_{EST}) (**Ru1** = 0.46 eV, **Ru2** = 0.40 eV, and **Ru3** = 0.31 eV, Fig. S46). Additionally, the formation of SCCs effectively confines the sonosensitizer within a rigid structure, minimizing the aggregation-induced ROS quenching effect. To evaluate the ROS quenching resistance, we assessed the ROS generation of **Ru1**, **Ru2**, and **Ru3** in various DMF/water mixtures (Fig. 2d). The results showed that, with increasing water content in the DMF/water mixture, the ROS generation of Rubpy decreased dramatically due to strong intermolecular π – π stacking interactions. In contrast, **Ru3** exhibited superior ROS quenching resistance, attributed to its rigid structure and the steric hindrance of the Ru acceptor.^{29–35} Furthermore, to investigate whether SCCs can



effectively generate ROS in deeper tissues, we studied the ROS penetration depth of **Ru3** in 1% lipid (solidified by 1% agarose) using a tissue model. The results revealed that **Ru3** achieved a penetration depth exceeding 10 cm (Fig. S47). In addition to the excellent sonodynamic performance exhibited by **Ru3** under US, its sonothermal properties have also been further evaluated (Fig. S48). Overall, **Ru3** demonstrated efficient ROS generation under US conditions, deep tissue ROS penetration, and excellent resistance to ROS quenching, underscoring its potential as a promising ferroptosis inducer.

Considering the redox enzyme-like activity demonstrated by **Ru3**-based agents, we next examined the catalytic activity of **Ru3** under conditions mimicking the intracellular environment. To evaluate the CAT-mimic activity of **Ru3**, we assessed its ability to decompose H_2O_2 into O_2 . Initially, $\text{Ru}(\text{dpp})_3\text{Cl}_2$ (RDPP) was used as an O_2 indicator to probe its CAT-mimic performance. RDPP is a well-known luminescent O_2 probe, widely used for O_2 detection and quantification.⁴⁸ The fluorescence of RDPP (with an emission maximum of 613 nm) was strongly quenched by molecular O_2 due to dynamic quenching (λ_{max} at 455 nm). As shown in Fig. 2e, under US conditions, **Ru3** induced a decrease in the fluorescence intensity of RDPP in buffer solution. Similarly, the increase in dissolved O_2 and the formation of gas bubbles supported substantial O_2 generation (Fig. 2f and S49). We also confirmed this by observing an increase in ROS levels upon the addition of H_2O_2 (Fig. S50). To assess the POD-mimic activity of **Ru3**, we measured its ability to induce $\cdot\text{OH}$ generation. As illustrated in Fig. 2g and S51, the characteristic absorption peak of MB at 665 nm underwent a pronounced reduction, coupled with visible color alterations following the addition of **Ru3**, thereby confirming the generation of $\cdot\text{OH}$. Similarly, by using tetramethylbenzidine (TMB) as a probe, which reacted with $\cdot\text{OH}$ to generate blue oxidized TMB with a characteristic absorption peak at 652 nm,⁴⁹ we observed a clear stronger absorption upon the addition of **Ru3** (Fig. S52).

GSH is a major endogenous antioxidant that plays a key role in maintaining redox homeostasis, capable of scavenging potential ROS bursts that may subsequently impair therapeutic outcomes.^{50,51} Given the redox properties of $\text{Ru}(\text{II})$, we further investigated the depletion of GSH in the presence of **Ru3**. To evaluate **Ru3**'s ability to consume GSH, we used 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) as a GSH indicator. DTNB can react with GSH to form 5-thio-2-nitrobenzoic acid (TNB).⁵² As shown in Fig. 2h, **Ru3** could induce a considerable amount of GSH depletion over time, fully demonstrating the effective depletion effect of **Ru3** on GSH. Then, ^1H NMR spectroscopy further verified the successful conversion of GSH to its oxidized form GSSG (Fig. S53). Also, cellular GSH can be regenerated from oxidized GSSG through a key NADPH-dependent process.⁵³ Therefore, we proceeded to investigate the sonocatalytic oxidation of NADPH by **Ru3**. The results showed that, upon addition of **Ru3**, the NADPH absorption at ~ 336 nm was significantly reduced with extended US exposure, and the NADPH oxidation turnover frequency (TOF) was 35.34 h^{-1} (Fig. 2i and S54). Similarly, ^1H NMR spectroscopy further validated the transformation of NADPH into its oxidized form, NADP^+ (Fig. S55). These observations suggested that **Ru3** exhibited CAT/POD-

mimic multi-enzyme activity and sonocatalyst-enhanced GSH and NADPH depletion, highlighting its significant potential for sonocatalyst-enhanced SDT in tumor cells ferroptosis (Fig. 2j).

In vitro cell uptake, localization, cytotoxicity and sonocatalytic activity studies

Given the excellent SDT performance demonstrated by the physicochemical properties of supramolecular sonosensitizers, we subsequently conducted *in vitro* experiments in 4T1 cells. First, inspired by the high-resolution imaging capabilities of **Ru3**, we evaluated its cellular uptake and localization. As shown in Fig. 3a and S56, after incubation with **Ru3**, 4T1 cells exhibited NIR-II fluorescence, which increased with incubation time and peaked at 24 hours. And the NIR-II fluorescence intensity of **Ru3** remained high during the 48-hour monitoring period. After determining the cellular uptake and retention efficiency of **Ru3**, we examined its subcellular localization to reveal its distribution within organelles. Incubation of 4T1 cells with **Ru3** and the LysoSensor Red probe (a commercial probe for lysosome imaging) for 30 min revealed that the NIR fluorescence signals from **Ru3** overlapped with the red fluorescence from LysoTracker Red, showing a Pearson correlation coefficient (PCC) of 0.81 (Fig. 3b). Likewise, **Ru3** fluorescence could well overlap with a commercial MitoTracker Red imaging probe (PCC = 0.72). These results suggested that **Ru3** effectively entered 4T1 cells and primarily concentrated in lysosomes and mitochondria, which is critical for its anticancer efficacy.⁵⁴ Then, we used the MTT assay to assess the cell viability of 4T1 cells after treatment with **Ru1–Ru3**. As shown in Fig. 3c and S57, the results indicated that **Ru3** exhibited negligible dark toxicity at low concentrations in the absence of US irradiation. When incubated with $10 \mu\text{M}$ of Rubpy, **Ru1**, **Ru2**, and **Ru3**, and conducted US irradiation, the cell viability of Rubpy, **Ru1**, **Ru2**, and **Ru3** decreased to 90%, 78%, 57%, and 35%, respectively, confirming that **Ru3** demonstrated significantly better performance in SDT compared to the other treatment groups.

To assess the potential of **Ru3** as a sonosensitizer adaptable to the tumor microenvironment, we then evaluated the O_2 levels within 4T1 cells using the RDPP staining method. As shown in Fig. 3d and S58, in the **Ru3**-treated group, a significant reduction in the red fluorescence of RDPP was observed, confirming an increase in O_2 levels within the 4T1 cells. Conversely, no substantial change in RDPP fluorescence was detected after Rubpy treatment, suggesting its limited O_2 production ability. These results indicated that **Ru3** may generate O_2 through the CAT-mimic process, alleviating hypoxia in 4T1 cells. Then, we incubated the SCC **Ru3** together with the DCFH probe to validate the effective ROS generation by **Ru3** in 4T1 cells. As shown in Fig. 3e, after incubation with **Ru3** and 4T1 cells without irradiation, a visible green fluorescence was observed, which may suggest that **Ru3**-mediated POD-mimic catalysis induced the generation of $\cdot\text{OH}$ within the cells. Upon US treatment, **Ru3** displayed a marked enhancement in green fluorescence compared to the Rubpy group, indicating US-triggered ROS generation. We further evaluated the POD-mimic activity by employing HPF as a $\cdot\text{OH}$ probe, and the results revealed






Fig. 3 *In vitro* cellular uptake, localization, cytotoxicity and sonocatalytic activity of SCC Ru3 in 4T1 cells. (a) Fluorescence images of 4T1 cells treated with Ru3 (10 μM) at different time points (0 h and 24 h). Scale bar: 10 μm. (b) Colocalization assay of Ru3 (10 μM) in 4T1 cells by using LysoTracker Red and MitoTracker Red. Scale bar: 10 μm. (c) Cell viabilities of 4T1 cells after incubation with different concentrations of Ru3 under US irradiation (1 W cm⁻²). Error bars represent mean ± SD (n = 3). (d) Fluorescence images of 4T1 cells co-incubated with RDPP under different treatments (Rubby: 10 μM, Ru3: 10 μM, and US irradiation: 1 W cm⁻²). Scale bar: 10 μm. (e) Fluorescence images of 4T1 cells co-incubated with DCF under different treatments. Scale bar: 25 μm. (f) Fluorescence images of 4T1 cells stained with HPF, incubated with Ru3 (10 μM) and irradiated with US (1 W cm⁻²). Scale bar, 10 μm. (g) Calcein-AM and PI-stained images of 4T1 cells after incubation with different treatments (Rubby: 10 μM, Ru3: 10 μM, and US power: 1 W cm⁻²). Scale bar, 25 μm. (h) Fluorescence images of GSH levels within the 4T1 cells after co-incubation with different treatment groups. (Rubby: 10 μM, Ru3: 10 μM, and US power: 1 W cm⁻²). Scale bar, 10 μm. (i) Relative NADPH activity in 4T1 cell under various treatments. Error bars represent mean ± SD (n = 3). (j) Cell viabilities of 4T1 cells co-incubated (24 h) with Ru3 (10 μM) and various inhibitors, Fer-1 (10 μM), 3-MA (10 μM), Z-VAD-FMK (10 μM) and Nec-1 (10 μM) under US irradiation (1 W cm⁻²). Error bars represent mean ± SD (n = 3).

a notable increase in HPF fluorescence intensity after Ru3 incubation, indicating the production of [•]OH *via* the POD-mimic mechanism in 4T1 cells (Fig. 3f). Finally, we used calcein AM and propidium iodide (PI) staining to distinguish live cells (green) from dead cells (red) (Fig. 3g). These results demonstrate that the Ru3 plus US group effectively generated ROS in 4T1 cells, showing enhanced sonodynamic performance.

Next, we investigated the consumption of GSH and the sonocatalytic oxidation of NADPH by Ru3 in 4T1 cells.

ThiolTrace Violet 500 was used as an indicator of intracellular GSH levels. As shown in Fig. 3h and S59, the green fluorescence of ThiolTrace Violet 500 in the Ru3-treated group was significantly diminished, indicating a reduction in GSH levels in 4T1 cells, which confirmed Ru3's consumption of intracellular GSH. In contrast, no significant change in fluorescence was observed in the Rubby-treated group, suggesting a weaker GSH depletion. After US irradiation, the green fluorescence in the Ru3 group almost completely disappeared, indicating that US-triggered ROS generation further depleted intracellular GSH.



Subsequently, the sonocatalytic oxidation of NADPH by **Ru3** in 4T1 cells was studied (Fig. 3i). After **Ru3** treatment and US irradiation, significant oxidation of NADPH was observed, consistent with our sonocatalytic studies.

Cell death mechanism studies

To explore the potential mechanisms of cell death under US irradiation, we assessed the cell viability of 4T1 cells in the presence of various cell death pathway inhibitors (Fig. 3j), including ferroptosis, autophagy, apoptosis and necrosis. After treatment with z-VAD-fmk (an apoptosis inhibitor) or necrostatin-1 (Nec-1, a necrosis inhibitor), cell viability remained almost unchanged, indicating non-apoptotic and non-necrotic cell death. In contrast, the addition of the ferroptosis inhibitor ferrostatin-1 (Fer-1) effectively increased the survival of 4T1 cells, suggesting that US-activated **Ru3** may induce ferroptosis. Furthermore, the autophagy inhibitor 3-methyladenine (3-MA) was found to partially improve cell viability, indicating that autophagic processes in lysosomes possibly contribute to this cell death mode.

Increasing evidence suggests that lysosome-targeting sonodynamic materials exhibit ferroptosis effects in tumor cells, which are more prominent than ROS-induced cell damage. Lysosomal membrane permeabilization (LMP) induces the release of various substances into the cytoplasm, such as protons and iron, which activate or amplify cell death signaling under iron depletion conditions.^{55–57} Similarly, mitochondrial dysfunction is a hallmark of ferroptosis. Cells undergoing ferroptosis often show dissipation of mitochondrial membrane potential (MMP), increased mitochondrial membrane permeability, and structural damage to mitochondria. MMP is essential for maintaining mitochondrial function and energy metabolism.^{58–61} Given that **Ru3** was primarily concentrated in both lysosomes and mitochondria, we then investigated the sonodynamic damage to lysosomes and mitochondria *in situ*. The JC-1 probe was used as a probe to detect the changes in MMP in cells. As shown in Fig. 4a, the **Ru3** plus US treatment group exhibited the strongest green fluorescence, indicating synergistic depolarization and mitochondrial membrane damage. Subsequently, using acridine orange (AO) as an indicator, the red fluorescence of AO in 4T1 cells treated with **Ru3** plus US disappeared dramatically compared to other treatments, indicating a loss of lysosomal integrity and dysfunction (Fig. 4b).

Previous studies have shown GSH depletion can inactivate GPX4, thereby upregulating ROS-dependent LPO, which is a crucial factor in ferroptosis-induced cell death.^{10–13,62} Considering the oxidative stress imbalance and GPX4 inactivation, we assessed the changes in LPO levels during the US-induced tumor cell death process. As shown in Fig. 4c and S60, the **Ru3** plus US treatment group exhibited significant LPO accumulation, as evidenced by the red fluorescence in the control group and the decrease in red fluorescence and an increase in green fluorescence in the **Ru3** plus US treatment group. Moreover, since malondialdehyde (MDA) is a key end product of LPO, we measured the MDA concentration in 4T1 cells treated under


different conditions. The results showed that the **Ru3** plus US group exhibited the highest MDA levels compared to other control groups (Fig. 4d). Additionally, transmission electron microscopy (TEM) analysis revealed morphological changes in 4T1 cell mitochondria, including mitochondrial shrinkage, increased membrane density, and decreased cristae, which are typical of ferroptosis-induced mitochondrial dysfunction (Fig. 4e).

To further investigate the ferroptosis induced by **Ru3** under US irradiation in 4T1 cells, we performed western blot (WB) analysis to detect the expression of ferroptosis-related proteins. As shown in Fig. 4f and S61, GPX4 expression was visibly reduced, which can be attributed to **Ru3**'s ability to deplete GSH, while US irradiation further exacerbated this depletion. These results suggest that the generation of multiple ROS, including $\cdot\text{OH}$ and $^1\text{O}_2$, and the depletion of GSH may together lead to irreversible GPX4 inactivation, consistent with the classical hallmark of ferroptosis. Additionally, we examined ferroptosis-related pathway markers, including Acyl-CoA synthetase long-chain family member 4 (ACSL4), which facilitates the esterification of polyunsaturated fatty acids (PUFAs) into PUFA-phospholipids (PUFA-PLs), which are prone to lipid peroxidation.^{63–66} WB analysis revealed that **Ru3** plus US treatment significantly upregulated the expression of ACSL4, further confirming that **Ru3** can induce ferroptosis in tumor cells. Previous reports have shown that oxidative stress can induce ferritinophagy and increase intracellular iron levels. This prompted us to explore whether ferritinophagy occurs in the cells. Nuclear receptor coactivator 4 (NCOA4) is known to be a key regulator of ferritinophagy, as it binds to ferritin and facilitates its transport to lysosomes for degradation.^{67–72} Notably, WB results showed a significant increase in NCOA4 expression, as well as in the LC3II/LC3I ratio and autophagy-related protein 5 (ATG5) following **Ru3** plus US treatment, which could be reversed by NAC treatment. Additionally, changes in the levels of the relevant proteins GPX4, ACSL4, and ACOA4 were further monitored through Raman signal variations, and the results were consistent with the ferroptosis outcomes (Fig. S62). Overall, the enzyme-like activity and sonocatalytic performance of **Ru3** enhanced ROS generation, induced ferritinophagy, depleted GSH and NADPH, and ultimately inhibited GPX4 activity, significantly promoting ferroptosis in tumor cells (Fig. 4g).

In vivo anticancer application

Given the excellent *in vitro* synergistic therapeutic effects of **Ru3**, we evaluated its *in vivo* antitumor efficacy using a 4T1 tumor-bearing mouse model. Before conducting *in vivo* experiments, we first performed hemolysis tests to ensure the biocompatibility of **Ru3** in biological systems (Fig. S63). Next, a total of 30 mice were randomly divided into 6 groups (5 mice per group): (1) control group, (2) US group, (3) Rubpy group, (4) Rubpy + US, (5) **Ru3** group, and (6) **Ru3** + US group. Mice in the Rubpy and **Ru3** groups were intratumorally injected with Rubpy (1 mg Ru per kg) and **Ru3** (1 mg Ru per kg), respectively, while the other groups received PBS. Following intratumoral injection





monitored body weight changes in the mice (Fig. 5d). The results indicated that the weight loss observed during treatment was negligible. Finally, on day 20, normal organs from each group of mice were collected for hematoxylin and eosin (H&E) staining. After 20 days of treatment, no significant organ damage was observed in any of the treatment groups (Fig. S65). It is noteworthy that the tumor tissue from the **Ru3** + US group exhibited a significantly lower cancer cell density compared to the other control groups, indicating the strong effectiveness of **Ru3**-mediated sonodynamic therapy. GPX4 immunofluorescence staining showed a marked downregulation in the **Ru3** + US group, suggesting that **Ru3**-induced ferroptosis plays a key




Fig. 5 *In vivo* antitumor experiments. (a) The protocol of the experiment. (b) Representative image of 4T1 tumor-bearing mice under different treatments at day 1 and day 14. (c) The linear curve depicts the 4T1 tumor suppression in different treatment groups. Error bars represent mean $\pm$ SD ($n = 5$). (d) Representative image depicts the body weight change of mice after various treatments. Error bars represent mean $\pm$ SD ($n = 5$). (e) H&E and GPX4 staining of tumor slices collected from tumor mouse models. Scale bar: H&E, 100 μ m; GPX4, 50 μ m.

role in its antitumor activity (Fig. 5d). These preliminary but comprehensive evaluations suggest that the sonosensitizer **Ru3** exhibits excellent biocompatibility and is suitable for potential *in vivo* therapeutic applications.

Conclusions

In conclusion, we successfully developed a series of supramolecular ferroptosis inducers (**Ru1–Ru3**) through a molecular engineering approach for NIR fluorescence-guided ferroptosis-enhanced SDT. Under US irradiation, **Ru3**, with its extended

π -conjugated system and enhanced ICT effect, demonstrated superior ROS generation. *In vitro* studies revealed that **Ru3** exhibited both CAT-mimic and POD-mimic catalytic activities, further boosting ROS production and broadening their diversity. Furthermore, **Ru3** catalyzed the depletion of GSH and promoted NADPH oxidation, disrupting cellular redox homeostasis, inducing autophagy, and triggering ferroptosis in 4T1 tumor cells. *In vivo*, **Ru3** effectively inhibited 4T1 tumor growth upon US activation with negligible side effects. This work offers a promising strategy for developing long-wavelength-emitting



supramolecular sonosensitizers, particularly for catalytically enhanced ferroptosis therapy with potential clinical applications.

Author contributions

Y. Sun conceived the project and designed the experiments. Y. Pang, C. Li and J. Zhang designed, synthesized and characterized the materials. L. Mei carried out theoretical calculations. Y. Luo and Q. Li performed the *in vitro* and *in vivo* studies. Y. Sun, Y. Pang, C. Li and J. Li wrote the manuscript. All authors analyzed and discussed the results and have given approval to the final version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Data availability

All the data supporting this article have been included in the main text and the SI. Supplementary information includes characterization data and synthesis steps of Ru1–Ru3; NMR spectra and MS spectra of Ru1–Ru3; cell imaging and therapeutic data, as well as *in vivo* imaging data. See DOI: <https://doi.org/10.1039/d5sc05712d>.

Acknowledgements

We thank the National Natural Science Foundation of China (22374055, 22022404, 22474047, and 22204055), the National Natural Science Foundation of Hubei Province (2022CFA033), and the Fundamental Research Funds for the Central Universities (2662025SYPY005).

References

- Y. D. Guo, P. Hu and J. L. Shi, *J. Am. Chem. Soc.*, 2024, **146**, 10217–10233.
- X. R. Wang, X. J. Song, Q. L. Wei, W. J. Wang, H. E. Xu and X. C. Dong, *Coord. Chem. Rev.*, 2024, **521**, 216189.
- G. Lei, L. Zhuang and B. Y. Gan, *Cancer Cell*, 2024, **42**, 513–534.
- Y. Zhang, X. Q. Zhang, H. C. Yang, L. Yu, Y. Xu, A. Sharma, P. Yin, X. Y. Li, J. S. Kim and Y. Sun, *Chem. Soc. Rev.*, 2021, **50**, 11227–11248.
- H. C. Yang, L. Tu, J. Li, S. Y. Bai, Z. X. Hu, P. Yin, H. Y. Lin, Q. Yu, H. D. Zhu and Y. Sun, *Coord. Chem. Rev.*, 2022, **453**, 214333.
- X. J. Xing, S. J. Zhao, T. Xu, L. Huang, Y. Zhang, M. H. Lan, C. W. Lin, X. L. Zheng and P. F. Wang, *Coord. Chem. Rev.*, 2021, **445**, 214087.
- Y. A. Martins, T. Z. Pavan and R. F. V. Lopez, *Int. J. Pharm.*, 2021, **610**, 121243.
- D. Li, Y. J. Zhu, W. W. Yin, X. T. Lin, G. Kim, Z. Y. Liu, S. W. Jung, J. Seo, S. Kim, J. S. Kim, H. Y. Huang and P. Y. Zhang, *Chem. Soc. Rev.*, 2025, **54**, 7610–7653.
- S. Son, J. H. Kim, X. W. Wang, C. L. Zhang, S. A. Yoon, J. Shin, A. Sharma, M. H. Lee, L. Cheng, J. S. Wu and J. S. Kim, *Chem. Soc. Rev.*, 2020, **49**, 3244–3261.
- F. T. Zeng, S. Nijati, L. G. Tang, J. M. Ye, Z. J. Zhou and X. Y. Chen, *Angew. Chem., Int. Ed.*, 2023, **62**, e202300379.
- N. Kang, S. Son, S. H. Min, H. Hong, C. Kim, J. An, J. Kim and H. Kang, *Chem. Soc. Rev.*, 2023, **52**, 3955–3972.
- N. Singh, D. Kim, S. Min, E. Kim, S. Kim, Y. S. Zhang, H. Kang and J. S. Kim, *Coord. Chem. Rev.*, 2025, **522**, 216236.
- S. K. Yao, F. W. Xu, Y. Wang, J. Z. Shang, S. M. Li, X. Y. Xu, Z. P. Liu, W. J. He, Z. J. Guo and Y. C. Chen, *J. Am. Chem. Soc.*, 2025, **147**, 11132–11144.
- L. Zhu, X. Y. Wang, T. Tian, Y. Y. Chen, W. J. Du, W. Wei, J. Zhao, Z. J. Guo and X. X. Wang, *Chem. Sci.*, 2024, **15**, 10499–10507.
- T. Xiong, Y. C. Chen, Q. Peng, S. Lu, S. R. Long, M. L. Li, H. Wang, S. Lu, X. Q. Chen, J. L. Fan, L. Wang and X. J. Peng, *Adv. Mater.*, 2024, **36**, 2309711.
- Q. Hu, W. J. Zhu, J. J. Du, H. Y. Ge, J. Z. Zheng, S. R. Long, J. L. Fan and X. J. Peng, *Chem. Sci.*, 2023, **14**, 9095–9100.
- W. Li, S. L. Yin, Y. Shen, H. Y. Li, L. Yuan and X. B. Zhang, *J. Am. Chem. Soc.*, 2023, **145**, 3736–3747.
- X. Q. Zhang, C. L. Li, Y. Zhang, X. F. Guan, L. C. Mei, H. L. Feng, J. Li, L. Tu, G. Q. Feng, G. Z. Deng and Y. Sun, *Adv. Funct. Mater.*, 2022, **32**, 2207259.
- Z. R. Gong and Z. F. Dai, *Adv. Sci.*, 2021, **8**, 2002178.
- C. Zhang and K. Y. Pu, *Adv. Mater.*, 2023, **35**, 2303059.
- Y. D. Pang, F. Zhao, Y. T. Wang, Q. Song, Q. Wang, J. R. Li, R. P. Zhang and Y. Sun, *Coord. Chem. Rev.*, 2025, **535**, 216664.
- Y. L. Wang, L. S. Luo, T. T. Zhang, J. R. Hu, H. L. Wang, F. Bao, C. L. Li, Y. Sun and J. R. Li, *ACS Appl. Mater. Interfaces*, 2024, **16**, 52068–52079.
- J. Zhu, C. C. Chu, D. S. Li, X. Pang, H. L. Zheng, J. Q. Wang, Y. S. Shi, Y. Zhang, Y. Cheng, E. Ren, J. L. Cheng, X. Y. Chen and G. Liu, *Adv. Funct. Mater.*, 2019, **29**, 1904056.
- Z. G. Chen, L. Sang, Y. J. Liu and Z. Q. Bai, *Adv. Sci.*, 2025, **12**, 2417439.
- S. Liang, J. J. Yao, D. Liu, L. Rao, X. Y. Chen and Z. H. Wang, *Adv. Mater.*, 2023, **35**, 2211130.
- Y. R. Yang, J. Huang, M. Liu, Y. G. Qiu, Q. H. Chen, T. J. Zhao, Z. X. Xiao, Y. Q. Yang, Y. T. Jiang, Q. Huang and K. L. Ai, *Adv. Sci.*, 2023, **10**, 2204365.
- X. M. Yao, W. Li, D. Fang, C. Y. Xiao, X. Wu, M. H. Li and Z. Luo, *Adv. Sci.*, 2021, **8**, 2100997.
- H. C. Yang, X. M. Yao, Y. Q. Liu, X. K. Shen, M. H. Li and Z. Luo, *ACS Nano*, 2023, **17**, 15328–15353.
- H. Sepehrpour, W. X. Fu, Y. Sun and P. J. Stang, *J. Am. Chem. Soc.*, 2019, **141**, 14005–14020.
- C. L. Li, Y. D. Pang, Y. L. Xu, M. J. Lu, L. Tu, Q. Li, A. Sharma, Z. Z. Guo, X. Y. Li and Y. Sun, *Chem. Soc. Rev.*, 2023, **52**, 5340–5342.
- D. D. Xu, Y. Li, S. C. Yin and F. H. Huang, *Chem. Soc. Rev.*, 2024, **53**, 3167–3204.
- Y. Qin, X. H. Chen, Y. X. Gui, H. Wang, B. Z. Tang and D. Wang, *J. Am. Chem. Soc.*, 2022, **144**, 12825–12833.
- Y. L. Xu, C. L. Li, S. Lu, Z. Z. Wang, S. Liu, X. J. Yu, X. P. Li and Y. Sun, *Nat. Commun.*, 2022, **13**, 2009.



- 34 Y. D. Pang, Q. Li, J. L. Wang, S. Y. Wang, A. Sharma, Y. L. Xu, H. Y. Hu, J. R. Li, S. Liu and Y. Sun, *Angew. Chem., Int. Ed.*, 2025, **64**, e202415802.
- 35 Y. Ding, Z. R. Tong, L. L. Jin, B. L. Ye, J. Zhou, Z. Q. Sun, H. Yang, L. J. Hong, F. H. Huang, W. L. Wang and Z. W. Mao, *Adv. Mater.*, 2022, **34**, 2106388.
- 36 B. X. Huang, X. Liu, G. L. Yang, J. Tian, Z. Y. Liu, Y. C. Zhu, X. P. Li, G. Q. Yin, W. Zheng, L. Xu and W. A. Zhang, *CCS Chem.*, 2022, **4**, 2090–2101.
- 37 K. Li, L. Y. Zhang, C. Yan, S. C. Wei, M. Pan, L. Zhang and C. Y. Su, *J. Am. Chem. Soc.*, 2014, **136**, 4456–4459.
- 38 S. Chen, K. Li, F. Zhao, L. Zhang, M. Pan, Y. Z. Fan, J. Guo, J. Y. Shi and C. Y. Su, *Nat. Commun.*, 2016, **7**, 13169.
- 39 C. Liang, J. E. Xie, S. L. Luo, C. Huang, Q. L. Zhang, H. Y. Huang and P. Y. Zhang, *Nat. Commun.*, 2021, **12**, 5001.
- 40 Y. L. Xu, Y. D. Pang, L. S. Luo, A. Sharma, J. F. Yang, C. L. Li, S. Liu, J. B. Zhan and Y. Sun, *Angew. Chem., Int. Ed.*, 2024, **63**, e202319966.
- 41 L. Yang, J. C. Huang, Y. N. Liao, D. P. Hu, Y. K. He, N. Feng, R. T. K. Kwok, J. W. Y. Lam, J. Zhang, B. Z. He and B. Z. Tang, *Adv. Healthcare Mater.*, 2025, **14**, 2500513.
- 42 J. Zhu, Y. Q. Zhu, J. H. Huang, W. J. Zhang, J. Q. Hou, B. Z. Tang and D. Wang, *Adv. Mater.*, 2025, **37**, 2502452.
- 43 C. Fu, W. Zhao, X. L. Wang, X. He, Y. T. Yin, J. Y. Li, Q. Y. Deng, C. H. Yan, Y. L. Yin, Z. M. Wang and R. Hu, *Aggregate*, 2025, **6**, e70058.
- 44 W. Zhao, C. Fu, H. Y. Gao, Y. Z. Zhou, C. H. Yan, Y. L. Yin, R. Hu and B. Z. Tang, *Mater. Chem. Front.*, 2023, **7**, 6229–6235.
- 45 C. L. Li, L. Tu, J. F. Yang, C. Liu, Y. L. Xu, J. R. Li, W. Tuo, B. Olenyuk, Y. Sun, P. J. Stang and Y. Sun, *Chem. Sci.*, 2023, **14**, 2901–2909.
- 46 L. Tu, C. L. Li, X. X. Xiong, J. H. Kim, Q. Li, L. C. Mei, J. R. Li, S. Liu, J. S. Kim and Y. Sun, *Angew. Chem., Int. Ed.*, 2023, **62**, e202301560.
- 47 Y. Li, F. H. Huang, P. J. Stang and S. C. Yin, *Acc. Chem. Res.*, 2024, **57**, 1174–1187.
- 48 B. J. Geng, J. Y. Hu, X. L. He, Z. L. Zhang, J. M. Cai, D. Y. Pan and L. X. Shen, *Adv. Mater.*, 2024, **36**, 2313670.
- 49 H. X. Zhang, J. Z. Lv, H. Wu, Y. H. He, M. Y. Li, C. H. Wu, D. Lv, Y. Y. Liu and H. Yang, *Sci. Adv.*, 2025, **11**, eadq3870.
- 50 Y. Zheng, W. J. Wang, J. X. Chen, K. Peng, X. X. Chen, Q. H. Shen, B. B. Liang, Z. W. Mao and C. P. Tan, *Adv. Sci.*, 2024, **12**, 2411629.
- 51 D. Wen, J. Feng, R. P. Deng, K. Li and H. J. Zhang, *Nat. Commun.*, 2024, **15**, 9359.
- 52 D. Li, M. H. Fan, H. B. Wang, Y. J. Zhu, B. L. Yu, P. Y. Zhang and H. Y. Huang, *Chem. Sci.*, 2024, **15**, 10027–10035.
- 53 P. P. Xue, H. L. Zhuang, S. J. Shao, T. J. Bai, X. M. Zeng and S. Q. Yan, *ACS Nano*, 2024, **18**, 25795–25812.
- 54 J. Zhou, Y. Z. Zhang, G. C. Yu, M. R. Crawley, C. R. P. Fulong, A. E. Friedman, S. Sengupta, J. F. Sun, Q. Li, F. H. Huang and T. R. Cook, *J. Am. Chem. Soc.*, 2018, **140**, 7730–7736.
- 55 Y. Li, B. Liu, Y. Zheng, M. Hu, L. Y. Liu, C. R. Li, W. Zhang, Y. X. Lai and Z. W. Mao, *J. Med. Chem.*, 2024, **67**, 16235–16247.
- 56 T. Feng, Z. X. Tang, J. Karges, J. Shu, K. Xiong, C. Z. Jin, Y. Chen, G. Gasser, L. N. Ji and H. Chao, *Chem. Sci.*, 2024, **15**, 6752–6762.
- 57 A. M. Wu, M. Li, Y. Y. Chen, W. Zhang, H. R. Li, J. Z. Chen, K. Gu and X. X. Wang, *Adv. Healthcare Mater.*, 2024, **13**, 2302556.
- 58 K. Q. Ma, H. Yang, T. R. Shen, Y. K. Yue, L. L. Zhao, X. G. Liu, F. J. Huo and C. X. Yin, *Chem. Sci.*, 2022, **13**, 3706–3712.
- 59 S. Wang, C. Chen, J. M. Wu, J. Y. Zhang, J. W. Y. Lam, H. Y. Wang, L. Chen and B. Z. Tang, *Sci. China:Chem.*, 2022, **65**, 870–876.
- 60 N. Montesdeoca, L. Johannknecht, E. Efanova, J. Heinen-Weiler and J. Karges, *Angew. Chem., Int. Ed.*, 2024, **63**, e202412585.
- 61 X. Tian, J. Y. Cheng, L. Yang, Z. X. Li and M. M. Yu, *Chem. Biomed. Imaging*, 2024, **2**, 518–525.
- 62 Y. S. Yang, X. L. Liu, D. Y. Xi, Y. B. Zhang, X. C. Gao, K. Xu, H. Y. Liu and M. X. Fang, *Chem. Biomed. Imaging*, 2024, **3**, 169–179.
- 63 S. Doll, B. Proneth, Y. Y. Tyurina, E. Panzilius, S. Kobayashi, I. IngoId, M. Irmeler, J. Beckers, M. Aichler, A. Walch, H. Prokisch, D. Trümbach, G. W. Mao, F. Qu, H. Bayir, J. Füllekrug, C. H. Scheel, W. Wurst, J. A. Schick, V. E. Kagan, J. P. F. Angeli and M. Conrad, *Nat. Chem. Biol.*, 2017, **13**, 91–98.
- 64 R. Li, X. J. Yan, C. C. Xiao, T. T. Wang, X. J. Li, Z. Y. Hu, J. L. Liang, J. B. Zhang, J. Y. Cai, X. Sui, Q. L. Liu, M. L. Wu, J. Q. Xiao, H. T. Chen, Y. S. Liu, C. H. Jiang, G. Lv, G. H. Chen, Y. C. Zhang, J. Yao, J. Zheng and Y. Yang, *Nat. Commun.*, 2024, **15**, 4760.
- 65 Y. Q. Wang, M. Z. Hu, J. Cao, F. X. Wang, J. R. Han, T. W. Wu, L. X. Li, J. S. Yu, Y. J. Fan, G. L. Xie, H. Y. Lian, Y. Y. Cao, N. Naowarojna, X. Wang and Y. L. Zou, *Cell*, 2025, **188**, 412–429.
- 66 X. Tian, J. Y. Cheng, L. Yang, Z. X. Li and M. M. Yu, *Chem. Biomed. Imaging*, 2024, **2**, 518–525.
- 67 Y. Y. Fang, X. C. Chen, Q. Y. Tan, H. H. Zhou, J. Xu and Q. Gu, *ACS Cent. Sci.*, 2021, **7**, 980–989.
- 68 A. Anandhan, M. Dodson, A. Shakya, J. J. Chen, P. F. Liu, Y. Y. Wei, H. Tan, Q. Wang, Z. Y. Jiang, K. Yang, J. G. N. Garcia, S. K. Chambers, E. Chapman, A. Ooi, Y. Yang-Hartwich, B. R. Stockwell and D. D. Zhang, *Sci. Adv.*, 2023, **9**, eade9585.
- 69 A. T. Ouyang, T. Chen, Y. Feng, J. H. Zou, S. Y. Tu, M. J. Jiang, H. M. Sun and H. B. Zhou, *Adv. Sci.*, 2024, **11**, 2404365.
- 70 C. Wang, F. Yuan, C. Fu, Y. Li, G. Dai, H. S. Kim, S. Xia, L. Yu, S. Debnath, W. X. Ren, J. Shu, M. Qiu and J. S. Kim, *J. Am. Chem. Soc.*, 2025, **147**, 136–148.
- 71 Q. Ding, C. Wang, H. Wang, C. Xiang, Z. Wang, Y. Wang, L. Zhao, M. Vendrell and J. S. Kim, *J. Am. Chem. Soc.*, 2025, **148**, 16661–16671.
- 72 J. Kim, Y. Xu, J. H. Lim, J. Y. Lee, M. Li, J. M. Fox, M. Vendrell and J. S. Kim, *J. Am. Chem. Soc.*, 2025, **147**, 701–712.

